Abbott Laboratories
Latest Abbott Laboratories News and Updates
Medtronic Expands Capabilities of Implantable Cardioverter Defibrillators
On May 2, 2016, the FDA approved Medtronic’s (MDT) Visia AF and Visia AF MRI Surescan. These devices are single-chamber implantable cardioverter defibrillators (or ICDs) capable of detecting asymptomatic and undiagnosed atrial fibrillation.
New Data Confirms the Efficiency of BSX’s HeartLogic Diagnostic
On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.
Bristol-Myers Squibb’s Immunoscience Products
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.
These Pfizer’s Products Are Now Losing Market Share
Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.
Inside Baxter International’s Stock Price Performance
On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.
Boston Scientific’s Updated 2017 Guidance
Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.
Boston Scientific Is Accelerating Category Leadership Strategy
Boston Scientific (BSX) currently has a global market opportunity of $40.0 billion, which is expected to grow to $50.0 billion by fiscal 2020.
Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health
Medtronics’ MITG (Minimally Invasive Therapies Group) business is expected to grow 3.5%–4.5%.
How Medtronic Is Delivering on Its Covidien Synergies
In January 2015, Medtronic (MDT) acquired Covidien for ~$43 billion in cash and MDT stock in a tax inversion deal.
Medtronic’s Emerging Market Position and Opportunities for Fiscal 2018
Medtronic (MDT) registered revenues of ~$1.0 billion revenues from emerging markets in fiscal 1Q18, which represents YoY (year-over-year) sales growth of ~11% in that market.
What Zimmer Biomet’s Leadership Transition Could Mean for Its Core Growth Strategy
In July 2017, David Dvorak stepped down as chief executive officer and president of Zimmer Biomet (ZBH) and resigned from its board of directors.
GlaxoSmithKline Reported Revenue Growth in 2Q17
GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.
Inside Novartis’s 2Q17 Revenues
Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.
Major Developments for Johnson & Johnson in 2Q17
Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]
Edwards Lifesciences Focuses on Indication Expansion of SAPIEN 3 in 2017
To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial.
Edwards Lifesciences’ Mitral Regurgitation Segment
To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015.
Edwards Lifesciences Focuses on Launch of SAPIEN 3 Ultra and CENTERA Valves
Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design.
Edwards Lifesciences: Focused on Inspiris Resilia and Konect
To extend the durability of the Inspiris Resilia surgical aortic valve, Edwards Lifesciences (EW) has incorporated a new tissue platform, Resilia tissue.
Can Edwards Intuity Elite Boost Edwards Lifesciences’ Revenues?
With the Edwards Intuity Elite valve system, Edwards Lifesciences aims to offer a minimally invasive therapy to complex aortic stenosis patients.
Transcatheter Heart Valve Therapy: Growth Driver for Edwards Lifesciences
In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.
GSK’s 2Q17 Earnings: Pharmaceuticals Segment
GSK’s Pharmaceuticals segment’s contribution to the company’s total revenues was 59.5% in 2Q17.
Behind Abiomed’s Plans to Create a Greater Awareness of Impella
To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.
Behind the Major Drivers of JNJ’s Medical Device Growth
Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16.
Medtronic’s Agreement Will Expand the Use of Its Tyrx Envelopes
Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections.
Medtronic Received Health Canada License for SureTune3
On June 6, 2017, Medtronic (MDT) received the Health Canada license for its SureTune3 software for DBS (deep brain stimulation) therapy.
What Drove Pfizer in 1Q17?
Growth drivers for Pfizer (PFE) include products contributing to operational growth, such as BMP2, Celebrex, Ibrance, Lyrica, and Xeljanz.
How Zimmer Biomet Stock Has Performed Recently
Zimmer Biomet Holdings (ZBH) was trading at $118.40 on May 30, 2017. It has a 50-day moving average of $119.70 and a 200-day moving average of $114.20.
Understanding Thermo Fisher’s Capital Deployment Strategy
Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).
Understanding Thermo Fisher’s Growth Strategy
Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.
How Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last?
Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.
Is Medical Technology Driving the US Healthcare Industry?
The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market.
What Dragged Down Technology Business Sales in 1Q17?
Dentsply Sirona’s Technology segment sales Dentsply Sirona (XRAY) reported ~$900 million of revenues worldwide in 1Q17. Of that, ~$389 million was generated through Dentsply Sirona’s Technology segment, which contributed ~43.2% to Dentsply Sirona’s total revenues. On a constant currency basis, the Technology segment’s sales declined by approximately 8.1%. The segment’s sales were flat in Europe. The […]
A Look at BD’s Deal Rationale in Its C.R. Bard Acquisition
BD’s acquisition of C.R. Bard is aimed at providing a comprehensive product portfolio to customers at more reasonable costs and enhanced efficiency.
These Pfizer Products Saw Declining Revenues in 2016
The overall share of revenues for the Essential Health Products business fell marginally to 44.7% of the total revenues for 2016 from 45.2% of the total revenues for 2015.
Inside Novartis’s Generics Performance in 4Q16
Sandoz, the Generics segment of Novartis (NVS), is second-largest generic medicines provider worldwide and number one in differentiated generics.
BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth
Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.
Johnson & Johnson’s Revenue Trend in 3Q16
In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues.
How Is Thermo Fisher Scientific’s FEI Integration Process Going?
Thermo Fisher Scientific (TMO) completed the acquisition of FEI Company on September 19, 2016.
Exploring the Nuances of Stryker’s Cost Transformation for Growth
Cost transformation growth is one of Stryker’s key strategies for driving growth. The company has come a long way from its decentralized structure prior to 2010.
Baxter International’s Recent Product Launches and Partnerships
Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.
Boston Scientific’s Acquisition of EndoChoice: Must-Know Details
On September 27, 2016, Boston Scientific (BSX) announced the acquisition of EndoChoice Holdings for $210 million.
The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics
On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.
How Danaher Diagnostics Fares against Its Competition
Danaher’s Diagnostics unit had operating margins of 15.4% in 2015 and 17.2% in 1H16.
The Key Product Lines That Make Up Danaher’s Diagnostics Business
Danaher’s (DHR) Diagnostics unit, established through the acquisition of Radiometer in 2004, earned $4.9 billion in sales in 2015.
Thermo Fisher Scientific’s Key Growth Strategy
Thermo Fisher Scientific reported ~$4.5 billion in revenues in 2Q16, representing YoY (year-over-year) growth of ~6%.
A Brief Look at the Technologies Segment Sales in 2Q16
In 2Q16, Dentsply Sirona’s leading position in the Digital Sensor category and rebound in the Lab business drove its Technologies segment sales.
Can Thermo Fisher’s PPI Business System Continue to Drive Growth in 2016?
The PPI system has helped nourish strong top-line growth across Thermo Fisher’s businesses while boosting margins.
What Drives Medtronic’s Cardiac Vascular Group’s Revenues?
Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment.
What’s the Verdict on Becton Dickinson’s Strategic Portfolio Review?
Becton Dickinson (BDX) completed its annual strategic review of its portfolio, which was initiated after the acquisition of CareFusion.
A Closer Look at Intuitive Surgical’s Business Strategy
Intuitive Surgical aims to include a larger patient population under its MIS treatments and to provide better surgery outcomes and lower recovery times.
